CAR-T therapy adapted for rare autoimmune disorder treatment.

A modified form of CAR-T therapy, known as Descartes-08, has shown promise in treating myasthenia gravis, an autoimmune disorder of the nervous system. The therapy targets the cells responsible for producing myasthenia gravis-causing antibodies and offers the potential for a longer-lasting reduction in symptoms. The therapy was well-tolerated without significant adverse effects in a small-scale clinical trial. The ideal dosage was determined to be once weekly for six weeks. The therapy is now being tested in a larger clinical trial to determine its ability to reduce myasthenia gravis symptoms.